An AGITG sub-study presented at ASCO, the world’s largest oncology meeting, shows the way people with colorectal cancer make decisions about their treatment.
The sub-study surveyed people who participated in the SCOT trial. In the SCOT trial people with colorectal cancer were randomly selected to receive either a three month course or a six month course of chemotherapy. This trial found that the three month course was just as effective as the six month course, meaning that chemotherapy could effectively be halved.
While they were undergoing treatment, patients were surveyed as part of the sub-study and asked how the potential side effects of a longer chemotherapy course weighed up against a longer life expectancy.
On average, patients said that if their life expectancy increased by three years they would undergo the six-month course of chemotherapy. This desired three year increase was the same whether their initial life expectancy was five years or 15 years.
These results were presented in a poster by Dr Prunella Blinman at the Annual Society of Clinical Oncology Annual Meeting in Chicago in June. Over 35,000 oncology professionals attended this meeting.
This sub-study was an important addition to the SCOT trial as it took note of how people took quality of life into account as well as their life expectancy. It showed that on average, people would prefer to have their life expectancy increased by a number of years if they were going to undergo the side effects associated with a longer course of chemotherapy.
Click below to view the poster:SCOT patient preferences sub-study poster
A summary of the SCOT trial is available here.